TALAZOPARIB TOSYLATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H14F2N6O.C7H8O3S
Molecular Weight	552.552
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(C=C1)S(O)(=O)=O.CN2N=CN=C2[C@@H]3[C@H](NC4=CC(F)=CC5=C4C3=NNC5=O)C6=CC=C(F)C=C6

InChI

InChIKey=QUQKKHBYEFLEHK-QNBGGDODSA-N

InChI=1S/C19H14F2N6O.C7H8O3S/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28;1-6-2-4-7(5-3-6)11(8,9)10/h2-8,15-16,24H,1H3,(H,26,28);2-5H,1H3,(H,8,9,10)/t15-,16-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C19H14F2N6O
Molecular Weight	380.3509
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C7H8O3S
Molecular Weight	172.202
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://adisinsight.springer.com/drugs/800033477https://www.ncbi.nlm.nih.gov/pubmed/23881923
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26652717 | https://www.ncbi.nlm.nih.gov/pubmed/23881923 | https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm

BMN-673 (8R,9S) is the (8R,9S) enantiomer of BMN-673, known as talazoparib. BMN 673 is a novel inhibitor of nuclear enzyme poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Poly [ADP-ribose] polymerase-1 23 Target ID: CHEMBL3105 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26652717	Inhibitor 8504		1.2 nM [Ki]
Poly [ADP-ribose] polymerase 2 16 Target ID: CHEMBL5366 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26652717	Inhibitor 8504		0.87 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2596
Breast cancer 432 Sources: http://adisinsight.springer.com/drugs/800033477 https://www.ncbi.nlm.nih.gov/pubmed/30506138	Primary	Approved 8583	TALZENNA Approved Use TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. Launch Date 2018
Ovarian cancer 160 Sources: http://adisinsight.springer.com/drugs/800033477	Primary	Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
9.97 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31489639/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
19.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31489639/	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
16.4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
193 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31489639/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
196 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31489639/	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
208 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
90 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
26% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1 mg 1 times / day steady, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: steady Dose: 1 mg, 1 times / day Sources: https://clincancerres.aacrjournals.org/content/clincanres/25/9/2717.full.pdf	unhealthy, 31 - 75 years Health Status: unhealthy Age Group: 31 - 75 years Sex: F Sources: https://clincancerres.aacrjournals.org/content/clincanres/25/9/2717.full.pdf	Disc. AE: Anemia, Function liver abnormal... Other AEs: Myelosuppression... AEs leading to discontinuation/dose reduction: Anemia (1 patient) Function liver abnormal (2 patients) Other AEs: Myelosuppression (23 patients) Sources: https://clincancerres.aacrjournals.org/content/clincanres/25/9/2717.full.pdf
1.1 mg 1 times / day multiple, oral MTD Dose: 1.1 mg, 1 times / day Route: oral Route: multiple Dose: 1.1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf	unhealthy, unknown Health Status: unhealthy Age Group: unknown Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf	Disc. AE: Thrombocytopenia, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Thrombocytopenia (grade 3, 16.67%) Thrombocytopenia (grade 4, 16.67%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf
1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	unhealthy, unknown Health Status: unhealthy Age Group: unknown Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	Other AEs: Decreased hemoglobin, Leukocyte count decreased... Other AEs: Decreased hemoglobin (grade 1-4, 90%) Leukocyte count decreased (grade 1-4, 84%) Neutropenia (grade 1-4, 68%) Lymphocyte count low (grade 1-4, 76%) Platelets decreased (grade 1-4, 55%) Glucose increased (grade 1-4, 54%) Aspartate aminotransferase increase (grade 1-4, 37%) Alkaline phosphatase increased (grade 1-4, 36%) Alanine aminotransferase increase (grade 1-4, 33%) Calcium decreased (grade 1-4, 28%) Decreased hemoglobin (grade 3, 39%) Leukocyte count decreased (grade 3, 14%) Neutropenia (grade 3, 17%) Lymphocyte count low (grade 3, 17%) Platelets decreased (grade 3, 11%) Glucose increased (grade 3, 2%) Aspartate aminotransferase increase (grade 3, 2%) Alkaline phosphatase increased (grade 3, 2%) Alanine aminotransferase increase (grade 3, 1%) Calcium decreased (grade 3, 1%) Leukocyte count decreased (grade 4, 0%) Neutropenia (grade 4, 3%) Lymphocyte count low (grade 4, 1%) Platelets decreased (grade 4, 4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf
1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf	unhealthy, unknown Health Status: unhealthy Age Group: unknown Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf	Disc. AE: Anemia, Accidental overdose... AEs leading to discontinuation/dose reduction: Anemia (2%) Accidental overdose (1%) Cerebral hemorrhage (1%) Dyspnea (1%) Glioblastoma multiforme (1%) Headache (1%) Metastases to meninges (1%) Neutropenia (1%) Chronic obstructive airways disease (1%) Thrombocytopenia (1%) Transient ischemic attack (1%) Vomiting (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf
1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf	unhealthy, unknown Health Status: unhealthy Age Group: unknown Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf	Other AEs: Anemia, Neutropenia... Other AEs: Anemia (32%) Neutropenia (15%) Thrombocytopenia (6%) Anemia (>5) Neutropenia (>5) Thrombocytopenia (>5) Platelet count decreased (>5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf
1 mg 1 times / day steady, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: steady Dose: 1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	unhealthy, unknown Health Status: unhealthy Age Group: unknown Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	Other AEs: Anemia, Neutropenia... Other AEs: Anemia (grade 1-4, 53%) Neutropenia (grade 1-4, 35%) Thrombocytopenia (grade 1-4, 27%) Decreased appetite (grade 1-4, 21%) Headache (grade 1-4, 33%) Nausea (grade 1-4, 49%) Vomiting (grade 1-4, 25%) Diarrhea (grade 1-4, 22%) Alopecia (grade 1-4, 25%) Fatigue (grade 1-4, 62%) Anemia (grade 3, 38%) Neutropenia (grade 3, 18%) Thrombocytopenia (grade 3, 11%) Decreased appetite (grade 3, <1%) Headache (grade 3, 2%) Nausea (grade 3, <1%) Vomiting (grade 3, 2%) Diarrhea (grade 3, 1%) Fatigue (grade 3, 3%) Anemia (grade 4, 1%) Neutropenia (grade 4, 3%) Thrombocytopenia (grade 4, 4%) Abdominal pain (19%) Dizziness (17%) Leukopenia (17%) Dysgeusia (10%) Dyspepsia (10%) Stomatitis (8%) Lymphopenia (7%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 CYP3A4/5 296 UGT1A1 246 UGT1A4 98 UGT1A6 136 UGT1A9 148 UGT2B7 197 UGT2B15 84 BSEP 550	P-gp 2052 BCRP 697 OAT1 395 OAT3 391 OCT1 393 OCT2 434 OATP1B1 503 OATP1B3 435 MATE1 182 MATE2 98 BSEP 63 hepatic enzymes 2	CYP1A2 832 CYP2B6 669

Drug as perpetrator

Target	Modality	Activity
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT1A1 303	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT1A4 100	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT1A6 171	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT1A9 155	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT2B15 84	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT2B7 210	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
hepatic enzymes 2	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	minor
BSEP 63	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
MATE1 182	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
MATE2 98	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OAT1 395	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OCT1 393	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 61-62	yes
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31770456/	yes	yes (co-administration study) Comment: itraconazole increases talazoparib AUC >50%; rifampicin did not inrease talazoparib AUC; both increased talazoparib plasma concentrations by 40% and 37%, respectively Sources: https://pubmed.ncbi.nlm.nih.gov/31770456/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 37.0

Sourcing

Vendor/Aggregator	ID	URL
AbMole Bioscience	1732	http://www.abmole.com/product.asp?id=1732
AbMole Bioscience	M1732	http://www.abmole.com/products/bmn673.html
Achemtek	0102-014244	http://www.achemtek.com/1207456-01-6
Acorn PharmaTech	ACN-053048	http://www.acornpharmatech.com/
AK Scientific, Inc. (AKSCI)	X5821	http://www.aksci.com/item_detail.php?cat=X5821
Ambinter	Amb24093138	http://www.ambinter.com/reference/24093138
ApexBio Technology	A3246	http://www.apexbt.com/bmn-673-8r-9s.html
Aurora Fine Chemicals LLC	K16.649.136	http://online.aurorafinechemicals.com/info?ID=K16.649.136
Aurum Pharmatech LLC	S-7826	http://www.Aurumpharmatech.com/Product/ProductDetails/S_7826
Axon MedChem	2502	https://www.axonmedchem.com/product/2502
BioCrick	BCC2205	http://www.biocrick.com/BMN-673-BCC2205.html
Boerchem	BC600324	http://www.boerchem.com/?product_43159.html
Chem Scene	CS-0937	http://www.chemscene.com/1207456-01-6.html
Chemspace	CSSB00015188901	https://chem-space.com/CSSB00015188901
Chemspace	CSSB00025726212	https://chem-space.com/CSSB00025726212
DC Chemicals	DC2008	http://www.dcchemicals.com/product_show-Talazoparib_BMN_673_.html
eNovation Chemicals	D596724	https://www.enovationchem.com/ProductDetails.asp?ProductID=D596724
eNovation Chemicals	Y0974305	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974305
Excenen	EX-A1356	http://www.excenen.com/searchresultlist.php?id=1207456-01-6
iChemical	EBD2207497	http://www.ichemical.com/products/1207456-01-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN01262559	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01262559
Matrix Scientific	131612	https://www.matrixscientific.com/131612.html
MedChem Express	HY-16106	https://www.medchemexpress.com/BMN-673.html
MolPort	MolPort-042-652-822	https://www.molport.com/shop/molecule-link/MolPort-042-652-822
MuseChem	I000776	https://www.musechem.com/product/I000776.html
Selleck Chemicals	S7048	http://www.selleckchem.com/products/bmn-673.html
Sinfoo Biotech	S061615	http://www.sinfoobiotech.com/product/1065028
Smolecule	S002091	http://www.smolecule.com/products/s002091
Smolecule	S548582	http://www.smolecule.com/products/s548582
Synblock Inc	SB16478	http://www.synblock.com/product/1207456-01-6.html
THE BioTek	bt-253535	https://www.thebiotek.com/product/inhibitors/bt-253535
THE BioTek	bt-287988	https://www.thebiotek.com/product/inhibitors/bt-287988

PubMed

Title	Date	PubMed
		25795821
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.	2010 Oct	20871615
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.	2012 Nov 1	23118055
Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone.	2014 Sep	25195882
PARP inhibitors: A new era of targeted therapy.	2015 May	25708226

Patents

Sample Use Guides

In Vivo Use Guide

Signs of activity of talazoparib were observed at 100 µg/day doses, and the maximum tolerated dose was 1.0 mg/day

Route of Administration: Oral

In Vitro Use Guide

Talazoparib (BMN 673) induces DNA damage at picomolar concentrations

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:44:55 GMT 2025` Edited by `admin` on `Mon Mar 31 21:44:55 GMT 2025`
Record UNII	02WK9U5NZC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TALZENNA

Preferred Name

English

TALAZOPARIB TOSYLATE

Official Name

English

TALAZOPARIB TOSYLATE [USAN]

Common Name

English

BMN 673TS

Code

English

Talazoparib tosylate [WHO-DD]

Common Name

English

(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one mono(4-methylbenzenesulfonate)

Systematic Name

English

TALAZOPARIB TOSILATE [JAN]

Common Name

English

BMN-673TS

Code

English

TALAZOPARIB TOSYLATE [ORANGE BOOK]

Common Name

English

TALAZOPARIB TOSYLATE [MI]

Common Name

English

3H-PYRIDO(4,3,2-DE)PHTHALAZIN-3-ONE, 5-FLUORO-8-(4-FLUOROPHENYL)-2,7,8,9-TETRAHYDRO-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-, (8S,9R)-, 4-METHYLBENZENESULFONATE (1:1)

Systematic Name

English

TALAZOPARIB TOSILATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C62554